Glenmark Pharmaceuticals Peer Comparison
NSE: GLENMARK | BSE: 532296
₹2,183.40
₹-15.10
(-0.69%)
As on 23-Oct-2026 09:34IST
Market cap
₹61,612 Cr
Revenue (TTM)
₹17,737 Cr
P/E Ratio
34.3
P/B Ratio
5.6
Div. Yield
0.1 %
Edit
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
61,612 | 1,07,954 | 30,160 | 25,975 | 26,309 |
Revenue (₹ Cr) |
17,737 | 7,270 | 3,564 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
1,797.81 | 1,090.76 | 414.00 | -371.81 | 387.35 |
Net Margin (%) |
9.86 | 14.89 | 11.23 | -3.93 | 26.01 |
RoE (%) |
30.87 | 21.64 | 8.38 | -3.85 | 25.18 |
Price to Earnings |
34.27 | 98.74 | 73.74 | -- | 68.12 |
Price-To-Book |
5.62 | 19.14 | 5.99 | 3.24 | 15.25 |
Income Statement (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
17,736.55 | 7,269.64 | 3,564.00 | 9,205.28 | 1,461.80 |
|
Total Income
|
18,236.50 | 7,323.34 | 3,686.00 | 9,449.59 | 1,489.25 |
|
Total Expenditure
|
12,939.86 | 5,235.79 | 2,792.00 | 8,195.15 | 919.25 |
|
EBITDA
|
4,796.69 | 2,033.85 | 772.00 | 1,010.13 | 542.56 |
|
Depreciation
|
616.73 | 487.08 | 226.00 | 857.51 | 37.68 |
|
EBIT
|
4,179.96 | 1,546.77 | 546.00 | 152.62 | 504.88 |
|
Interest
|
204.50 | 161.45 | 217.00 | 342.73 | 3.77 |
|
Other Income
|
499.94 | 53.70 | 122.00 | 244.31 | 27.45 |
|
Exceptional Items
|
-1,942.85 | 0.00 | 12.00 | -216.88 | 0.00 |
|
Profit before Tax
|
2,532.56 | 1,439.02 | 463.00 | -162.68 | 528.56 |
|
Provision for Tax
|
734.75 | 348.26 | 49.00 | 209.13 | 141.21 |
|
Profit after Tax
|
1,797.81 | 1,090.76 | 414.00 | -371.81 | 387.35 |
Liabilities (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
10,512.11 | 5,300.06 | 4,940.00 | 8,162.62 | 1,653.56 |
|
Minority Interest
|
0.10 | 2.84 | -5.00 | 0.00 | -1.13 |
|
Non-Current Liabilities
|
3,019.66 | 1,444.40 | 1,712.00 | 5,044.14 | 42.40 |
|
Current Liabilities
|
6,376.43 | 3,635.43 | 1,622.00 | 4,758.28 | 230.82 |
|
Total Liabilities
|
19,906.65 | 10,511.19 | 8,578.00 | 17,723.32 | 1,983.96 |
Assets (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
7,567.18 | 5,220.48 | 5,343.00 | 10,211.52 | 1,026.85 |
|
Current Assets
|
11,299.71 | 4,829.21 | 2,606.00 | 7,191.66 | 881.27 |
|
Total Assets
|
19,906.65 | 10,511.19 | 8,578.00 | 17,723.32 | 1,983.96 |
|
Total Debt*
|
0.00 | 2,397.49 | 2,125.00 | 5,495.48 | 26.49 |
|
Net Current Assets
|
4,923.28 | 1,193.78 | 984.00 | 2,433.38 | 650.46 |
|
Contingent Liabilities
|
787.81 | 420.55 | 768.26 | 95.72 | 17.25 |
Cashflow (₹ Cr)
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
3,445.03 | 1,623.50 | 390.00 | 1,652.60 | 292.17 |
|
Cash Flow from Investing Activities
|
-1,283.23 | -1,088.66 | -241.00 | -826.03 | -265.94 |
|
Cash from Financing Activities
|
-2,708.75 | -524.72 | -54.00 | -38.98 | 4.10 |
|
Net Cash Inflow / Outflow
|
-546.95 | 10.12 | 95.00 | 787.59 | 30.33 |
Ratios
Profitability Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
20.35 | 18.20 | 6.79 | 1.24 | 32.42 |
|
ROE (%)
|
30.87 | 21.64 | 8.38 | -3.85 | 25.18 |
|
ROA (%)
|
10.00 | 10.99 | 4.94 | -2.21 | 21.93 |
|
EBIT Margin (%)
|
23.57 | 21.28 | 15.32 | 1.66 | 34.54 |
|
Net Margin (%)
|
9.86 | 14.89 | 11.23 | -3.93 | 26.01 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
32.94 | 22.62 | 18.37 | 0.78 | 40.90 |
|
EBIT Growth (%)
|
126.49 | 87.41 | 252.26 | -70.53 | 124.50 |
|
Net Profit Growth (%)
|
138.48 | 116.73 | 377.85 | -1,383.43 | 104.15 |
|
EPS Growth (%)
|
174.53 | 114.66 | 1,001.33 | -484.84 | 42.32 |
|
Book Value Growth (%)
|
18.53 | 18.63 | 13.47 | 0.33 | 26.03 |
Valuation Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
19.87 | 98.68 | 75.69 | -83.01 | 68.12 |
|
Price / Book Value
|
5.62 | 19.14 | 5.99 | 3.24 | 15.25 |
|
Dividend Yield (%)
|
0.11 | 0.10 | 0.00 | 0.00 | 0.08 |
|
EV/EBITDA
|
12.60 | 54.20 | 40.96 | 29.81 | 48.13 |
|
Market Cap (₹ Cr)
|
60,201.30 | 53,545.31 | 19,071.62 | 18,108.89 | 20,944.75 |
Solvency Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.12 | 0.31 | 0.53 | 0.02 |
|
Short term debt to equity ratio
|
-- | 0.28 | 0.09 | 0.09 | 0.02 |
|
Current Ratio
|
1.77 | 1.33 | 1.61 | 1.51 | 3.82 |
|
Quick Ratio
|
1.23 | 0.68 | 1.06 | 0.87 | 2.82 |
|
Interest Coverage
|
13.38 | 9.91 | 3.13 | 0.53 | 141.16 |
Operating Efficiency Ratios
| Glenmark Pharmaceuticals | Laurus Labs | Wockhardt | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
27.98 | 29.64 | 16.50 | 23.44 | 24.80 |
|
Asset Turnover
|
0.99 | 0.73 | 0.43 | 0.55 | 0.83 |
|
Receivable days
|
43.78 | 111.49 | 58.75 | 78.20 | 88.98 |
|
Inventory Days
|
34.05 | 114.62 | 75.82 | 93.30 | 56.04 |
|
Payable days
|
264.58 | 155.13 | 186.21 | 226.14 | 99.95 |
|
Cash Conversion Cycle
|
-186.74 | 70.98 | -51.64 | -54.64 | 45.07 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
